HUAPONT PHARM.

ABOUT HUAPONT

重庆华邦制药有限公司环境信息公开表


关于阿斯利康阿那曲唑相关专利无效的公告


2019年4月阿斯利康向苏州市中级人民法院起诉华邦制药“侵害发明专利权纠纷”,提出我司产品阿那曲唑片(瑞婷)侵犯该公司第02824544.X号发明专利(阿那曲唑在制备用于治疗患有早期乳腺癌的绝经后的妇女的药物方面的用途)。

重庆华邦胜凯制药有限公司环境信息公开表


Moxifloxacin was approved in Japan


On February 10, 2020, Chongqing Huapont Pharmaceutical Co., Ltd. obtained the "Notice of Pharmaceutical Compliance Investigation Results" issued by the Japanese competent authority PMDA (Pharmaceuticals and Medical Devices Agency).

重庆华邦制药有限公司环境信息公开表


Huapont-Shimadzu Cooperative Laboratory Established


As good cooperation between our company and Shimadzu Enterprise Management (China) Co., Ltd. for a long time , it is decided to jointly build a cooperative laboratory based on the needs of their future development strategies and to continually strengthen the cooperative relationship between the two parties.

重庆华邦胜凯制药有限公司长寿分公司原料药生产项目 环境影响评价公众参与第二次公示


重庆华邦胜凯制药有限公司环保公示


< 123 > proceed page